Blog
RSS FeedPosted by Michael Wonder on 22 Dec 2024
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
20 December 2024 - For the first time, NICE has recommended an innovative new treatment to help stop babies, children and ...
Posted by Michael Wonder on 18 Dec 2024
Ublituximab for the treatment of patients with relapsing multiple sclerosis
18 December 2024 - NICE has published final Evidence-based recommendations on the use of ublituximab (Briumvi) for the treatment of adults ...
Posted by Michael Wonder on 18 Dec 2024
What is NICE’s severity modifier?
15 December 2024 - A guide to the severity modifier and how it is leading to more positive recommendations overall from ...
Posted by Michael Wonder on 12 Dec 2024
Toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced oesophageal squamous cell cancer
11 December 2024 - NICE is unable to make a recommendation on the use in the NHS of toripalimab (Loqtorzi) in ...
Posted by Michael Wonder on 12 Dec 2024
Elranatamab for treating relapsed and refractory multiple myeloma after three or more treatments (final guidance)
11 December 2024 - NICE has published final evidence-based recommendations on the use of elranatamab (Elrexfio) for the treatment of ...
Posted by Michael Wonder on 10 Dec 2024
New price deal paves way for NICE approval of treatment for rare genetic condition
10 December 2024 - A new treatment for Duchenne muscular dystrophy is set to be available to around 1,700 people in ...
Posted by Michael Wonder on 09 Dec 2024
Cladribine for the treatment of patients with relapsing multiple sclerosis
6 December 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Dec 2024
Ruxolitinib phosphate for the treatment of patients with acute graft versus host disease that responds inadequately to corticosteroids
6 December 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Dec 2024
Molnupiravir for the treatment of patients with COVID-19 infection
26 November 2024 - NICE has published further draft guidance on the use of molnupiravir (Lagevrio) in the NHS in ...
Posted by Michael Wonder on 06 Dec 2024
NICE describes how weight loss drug tirzepatide will be rolled out
5 December 2024 - The medication will initially be offered only to those people with the highest clinical needs. ...
Posted by Michael Wonder on 06 Dec 2024
Does NICE’s “severity modifier” for assessing diseases need to change?
22 November 2024 - Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in ...
Posted by Michael Wonder on 04 Dec 2024
Fedratinib dihydrochloride monohydrate for the treatment of adults with disease-related splenomegaly or symptoms in myelofibrosis
20 November 2024 - NICE has published final evidence-based recommendations on the use of fedratinib dihydrochloride monohydrate (Inrebic) for the ...
Posted by Michael Wonder on 30 Nov 2024
NICE responds to failure of talks to reach price agreement on Enhertu
19 November 2024 - Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu ...
Posted by Michael Wonder on 19 Nov 2024
Zilucoplan sodium for the treatment of patients with antibody positive generalised myasthenia gravis (revised draft guidance)
14 November 2024 - NICE has produced updated guidance on the use of zilucoplan sodium in the NHS in England. ...
Posted by Michael Wonder on 16 Nov 2024
New study shows NICE advice support can reduce appraisal timelines by 3 months
14 November 2024 - Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance ...